Gladden Longevity

What You Don’t Know About Hyperbaric Oxygen Therapy – Episode 170

Join Dr. Jeffrey Gladden, Steve Reiter and Dr. Paul Harch in this episode of the Gladden Longevity podcast. Paul G. Harch, M.D. is a clinical private practice and academic physician who made a discovery in 1989 treating divers with chronic brain decompression illness.  He found that the wounds in these divers’ brains were similar to chronic extremity wounds, but they were only responsive to a non-traditional dose of hyperbaric oxygen therapy. In 2004, based on the life-extending outcomes of treating patients with dementia, he proposed the longevity potential of HBOT to the American Academy of Anti-Aging Medicine.  In March 2020, he proved the efficacy of HBOT in mild TBI persistent post-concussion syndrome in a randomized controlled trial and proposed HBOT application to COVID. Now in its 3rd edition, HBOT is explained as an epigenetic therapy with expected revolutionary effects on medicine, neurology, and longevity. In this episode, they talk about HBOT as a dual-component drug, the primary target of HBOT, and how HBOT is a treatment for wounds and inflammatory conditions in any location and of any duration. Do you know the medical benefits of HBOT? Listen to find out more. 

Listen to this episode to learn about making a 100 the new 30 and Living Young for a Lifetime!

Discount code:  

Longevity10 (for 10% off your purchase at the Gladden Longevity Supplement shop

Show Notes:

Dr. Gladden considers Dr. Harch to be one of the fathers or grandfathers of hyperbaric oxygen therapy (00:58). 

Dr. Harch explains what drew him into researching hyperbaric oxygen therapy. (1:35) 

Dr. Harch discusses why hyperbaric oxygen therapy is used for scuba divers or diving medicine. (3:05) 

Dr. Harch mentions how important the first hour is when using hyperbaric oxygen to treat injuries divers may have. (6:05) 

Dr. Gladden shares that molecular hydrogen is a way to modulate reperfusion injury. (7:00) 

Dr. Harch notes that if you can give the hyperbaric treatment in the first hour, it totally inhibits those attachment molecules on the white blood cells from expressing themselves. (9:45) 

Dr. Harch says all coastal facilities that treat divers do not get the same results the US Navy does. (11:15) 

Dr. Gladden infers that everything is in its own balance. (13:10) 

Dr. Harch clarifies that barometric pressure is a separate entity from oxygen. (15:14) 

Dr. Harch mentions that only a few people have used dosing as a primary method of treatment. (18:15) 

Dr. Harch elaborates on hypoxia-inducing factors. (21:44) 

Dr. Harch says there is a whole literature now on hyperbaric oxygen preconditioning. (23:08) 

Dr. Harch expresses that if you give two hyperbaric treatments a night before cardiac surgery, you significantly reduce the cognitive insult that results after surgery. (25:40) uses the promo code longevity10 to get a 10 percent discount. (28:55) 

Dr. Harch argues that doctors are trained and taught reimbursable medicine. (30:17) 

Dr.  Harch discloses that so much of brain diseases are caused by problems in the white matter. (33:07) 

Dr. Harch reveals his treatment approach. (36:45) 

Dr. Harch specifies that he has treated 130 drowned children over the years. (39:50) 

Dr. Harch recounts his interaction with the FDA some time back. (43:23) 

Dr. Harch gives reasons why people may not benefit from hyperbaric chambers. (46:33) 

Dr. Gladden points out how inflammation becomes a problem as people get older. (49:15) 

Dr. Harch recalls going to the NIH and FDA to seek funding for studies. (52:25) 

Dr. Harch testifies that he has treated many dementia patients and shares that hyperbaric treatment prolongs their lives. (57:05) 

Dr. Harch confesses that hyperbaric oxygen has limited or no effect on ALS by itself. (59:08) 

To learn more about Dr. Paul Harch’s work check out the following:


Phone number: 504-309-4948 


Recent Episodes

Follow us


For more information on our practice or how to become a client, visit:
Call us: 972-310-8916
Or email us:

Leave a Reply

Your email address will not be published. Required fields are marked *